Impact of EML4-ALK variants and co-occurring TP53 mutations on duration of first-line ALK tyrosine kinase inhibitor treatment and overall survival in ALK fusion-positive NSCLC: Real-world outcomes from the GuardantINFORM database

Lung, Respiratory and Thoracic Cancer

Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)

Lung Cancer

Ou SH, Kilvert H, Candlish J, Lee B, Polli A, Thomaidou D, Le H

doi: 10.1016/j.lungcan.2024.107968

Lung, Respiratory and Thoracic Cancer

Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer

Lung Cancer

Bauman JR, Liu G, Preeshagul I, Liu SV, Melosky B, Abrahami D, Li B, Thomaidou D, Duncan K, Krulewicz S, Rupp M, Lin JJ

doi: 10.1016/j.lungcan.2024.107919

EHA 2024

Leukemia

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

SPECIAL REPORT

Lung, Respiratory and Thoracic Cancer

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

Lung, Respiratory and Thoracic Cancer

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

JTO Clin Res Rep

Lucibello F, Gounant V, Aldea M, Duruisseaux M, Perol M, Chouaid C, Bennouna J, Fallet V, Renault A, Guisier F, Giroux-Leprieur E, Wislez M, Toffart AC, Mazieres J, Basse C, Hegarat N, Carton M, Girard N

doi: 10.1016/j.jtocrr.2024.100743

Further Publications

Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

Eur J Cancer

Mortier L, Blom A, van Hille B, Samimi M, Luciani L, Cahuzac C, Robert C, Quereux G, Maubec E, Miotti H, Maillard C, Aubin F, Lenormand C, Solbes MN, Joly P, Kachaner I, Lebbé C, Dutriaux C, Saiag P

doi: 10.1016/j.ejca.2024.114261

SABCS 2024

Breast Cancer

Advancing Breast Cancer Treatment with Elacestrant

Lung, Respiratory and Thoracic Cancer

Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study

Lung Cancer

Uprety D, Abrahami D, Marcum ZA, Li B, Sang A, Davis M, Rifi N, Kelton JM, Ramaswamy K, Sanghvi P, Bazhenova L

doi: 10.1016/j.lungcan.2025.108436

Lung, Respiratory and Thoracic Cancer

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment

JTO Clin Res Rep

Schmid S, Holer L, Gysel K, Koster KL, Rothschild SI, Boos LA, Frehner L, Cardoso Almeida S, Britschgi C, Metaxas Y, Mark M, Froesch P, Janthur WD, Allemann A, Waibel C, Von der Mühll-Schill C, Früh M, Mauti LA

doi: 10.1016/j.jtocrr.2024.100735

Related content

Systematic review and network meta-analysis of lorlatinib with comparison to other anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitors (TKIs) as first-line treatment for ALK-positive advanced non-smallcell lung cancer (NSCLC)

Real-world treatment sequencing and effectiveness of second- and third-generation ALK tyrosine kinase inhibitors for ALK-positive advanced non-small cell lung cancer

Real-world study showed that initiating the next treatment was significantly more common among patients treated with first-line acalabrutinib versus first-line ibrutinib

Navigating the Evolving Treatment Paradigm for Advanced EGFR-mutated NSCLC

Real-World Outcomes of Pralsetinib in RET Fusion-Positive NSCLC

Avelumab as second-line or later treatment in patients with metastatic Merkel cell carcinoma: Analysis of real-world outcomes in France using the CARADERM database linked to the French national healthcare database

Advancing Breast Cancer Treatment with Elacestrant

Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study

Real-World Outcomes of Patients With Malignant Pleural Mesothelioma Receiving a Combination of Ipilimumab and Nivolumab as First- or Later-Line Treatment